Eupraxia Pharmaceuticals Inc. a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effective immediately.

Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities.

"Having previously served as Eupraxia's CFO, and after that as our capital markets consultant, we are delighted to have Alex return and take over from Bruce. I believe his public markets and deal expertise, and his deep familiarity with Eupraxia and its shareholders, will make Alex a key contributor to our senior leadership team as Eupraxia advances its programs in EP-104GI and EP-104AR," said James Helliwell, Chief Executive Officer of Eupraxia.

"On behalf of our board of directors, I'd like to thank Bruce for his leadership and many important contributions to Eupraxia's success including the Company's recent Nasdaq listing, and his efforts strengthening our balance sheet, which gives us a solid foundation to build on."

Based in Victoria, B.C., Mr. Rothwell brings more than 25 years of experience as a business leader and as a senior executive in the Canadian capital markets and investment banking. He previously served as the CFO of Eupraxia from 2018-2021, and most recently has been a Senior Advisor to Fort Capital Partners, a Canadian boutique investment bank.

In 1995, he began his capital markets career in institutional equities and merger arbitrage, establishing himself over the next decade in various leadership roles at leading Canadian investment banks. He was appointed President and Executive Director of Macquarie Capital Markets Canada and ran its equities business for seven years before moving to British Columbia in late 2015.

Eupraxia is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat.

We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy, and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease, and other critical disease areas.

Source: prnewswire.com

Report Abuse